Treatment with AMR101 at both doses resulted in lower overall cholesterol compared to placebo when levels of HDL or "good" cholesterol were factored in. By comparison, Glaxo's Lovaza causes an increase in the level of LDL or "bad" cholesterol, which is one reason why the drug's use is restricted to patients with very high baseline triglyceride levels. Amarin is conducting a second phase III study of AMR101 enrolling patients with lower or "mixed" baseline levels of triglyceride, with results expected next year. Amarin is also expected to seek a partner for AMR101 or sell the company outright. Glaxo acquired rights to Lovaza when it purchased Reliant Pharmaceuticals in 2007 for $1.6 billion. Lovaza generates about $1 billion in annual sales. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.